Agilent Technologies, Inc. and SomaLogic, Inc. have entered into an agreement to expand access to SomaLogic’s unbiased protein biomarker discovery platform. The companies will initially place SomaLogic’s SOMAscan proteomic assay, which employs custom Agilent microarrays in its workflow, in select academic and contract research centers. Terms of the agreement were not disclosed.
“This agreement will greatly enhance our current microarray offerings by expanding them into the rapidly growing proteomics market,” said Jacob Thaysen, vice president and general manager of Agilent’s Genomics Solutions Division. “SomaLogic’s cutting-edge proteomic technology makes them an ideal partner for us to increase our presence in this growing market.”
“Agilent’s custom microarrays have been a critical element in our development of the SOMAscan assay over the past several years,” said Larry Gold, Ph.D., chairman and chief executive officer of SomaLogic. “We are delighted that our partnership is expanding to make the technology even more accessible to researchers everywhere.”